OBJECTIVES/HYPOTHESIS: To evaluate antitumor efficacy of the generic mammalian target of rapamycin (mTOR) inhibitor sirolimus in preclinical animal models of head and neck squamous cell carcinoma (HNSCC) and compare its effects with those of the patented analogue temsirolimus. STUDY DESIGN: In vivo study. METHODS: To develop xenograft established tumor model (ETM) of HNSCC, FaDu cells were injected subcutaneously into nude mice. When tumors reached 50 to 60 mm(3), mice were randomized into five groups and treated daily intraperitoneally with sirolimus at various doses for 5 days per week for 3 weeks. Tumor volumes were measured. The results were compared with historical data on temsirolimus effects. In the minimal residual disease (MRD) model, surgical wounds were created and FaDu cells implanted. After 72 hours, animals were randomized into two groups and were injected intraperitoneally with 0 or 5 mg/kg sirolimus for 5 days per week for 30 days. RESULTS: In the ETM, sirolimus significantly inhibited tumor growth (P < .01), although there was no overall significant difference in tumor growth inhibition between sirolimus and temsirolimus. In the MRD model, sirolimus significantly suppressed growth of tumors (P < .001) and improved survival compared with controls (P < .01). There was a significant decrease in pS6 expression, indicating mTOR inhibition. CONCLUSIONS: In this study, we demonstrate that the generic mTOR inhibitor sirolimus shows potent antitumor activity in HNSCC and produces comparable effects to the patent drug temsirolimus. Sirolimus has the potential of serving as an economic and comparative targeted agent to temsirolimus in the treatment of HNSCC.
OBJECTIVES/HYPOTHESIS: To evaluate antitumor efficacy of the generic mammalian target of rapamycin (mTOR) inhibitor sirolimus in preclinical animal models of head and neck squamous cell carcinoma (HNSCC) and compare its effects with those of the patented analogue temsirolimus. STUDY DESIGN: In vivo study. METHODS: To develop xenograft established tumor model (ETM) of HNSCC, FaDu cells were injected subcutaneously into nude mice. When tumors reached 50 to 60 mm(3), mice were randomized into five groups and treated daily intraperitoneally with sirolimus at various doses for 5 days per week for 3 weeks. Tumor volumes were measured. The results were compared with historical data on temsirolimus effects. In the minimal residual disease (MRD) model, surgical wounds were created and FaDu cells implanted. After 72 hours, animals were randomized into two groups and were injected intraperitoneally with 0 or 5 mg/kg sirolimus for 5 days per week for 30 days. RESULTS: In the ETM, sirolimus significantly inhibited tumor growth (P < .01), although there was no overall significant difference in tumor growth inhibition between sirolimus and temsirolimus. In the MRD model, sirolimus significantly suppressed growth of tumors (P < .001) and improved survival compared with controls (P < .01). There was a significant decrease in pS6 expression, indicating mTOR inhibition. CONCLUSIONS: In this study, we demonstrate that the generic mTOR inhibitor sirolimus shows potent antitumor activity in HNSCC and produces comparable effects to the patent drug temsirolimus. Sirolimus has the potential of serving as an economic and comparative targeted agent to temsirolimus in the treatment of HNSCC.
Authors: Cherie-Ann O Nathan; Nazanin Amirghahari; Xiaohua Rong; Tony Giordano; Don Sibley; Mary Nordberg; Jonathan Glass; Anshul Agarwal; Gloria Caldito Journal: Cancer Res Date: 2007-03-01 Impact factor: 12.701
Authors: Panomwat Amornphimoltham; Vyomesh Patel; Akrit Sodhi; Nikolaos G Nikitakis; John J Sauk; Edward A Sausville; Alfredo A Molinolo; J Silvio Gutkind Journal: Cancer Res Date: 2005-11-01 Impact factor: 12.701
Authors: R Salgo; J Gossmann; H Schöfer; H G Kachel; J Kuck; H Geiger; R Kaufmann; E H Scheuermann Journal: Am J Transplant Date: 2010-02-01 Impact factor: 8.086
Authors: Andreas A Schnitzbauer; Carl Zuelke; Christian Graeb; Justine Rochon; Itxarone Bilbao; Patrizia Burra; Koert P de Jong; Christophe Duvoux; Norman M Kneteman; Rene Adam; Wolf O Bechstein; Thomas Becker; Susanne Beckebaum; Olivier Chazouillères; Umberto Cillo; Michele Colledan; Fred Fändrich; Jean Gugenheim; Johann P Hauss; Michael Heise; Ernest Hidalgo; Neville Jamieson; Alfred Königsrainer; Philipp E Lamby; Jan P Lerut; Heikki Mäkisalo; Raimund Margreiter; Vincenzo Mazzaferro; Ingrid Mutzbauer; Gerd Otto; Georges-Philippe Pageaux; Antonio D Pinna; Jacques Pirenne; Magnus Rizell; Giorgio Rossi; Lionel Rostaing; Andre Roy; Victor Sanchez Turrion; Jan Schmidt; Roberto I Troisi; Bart van Hoek; Umberto Valente; Philippe Wolf; Heiner Wolters; Darius F Mirza; Tim Scholz; Rudolf Steininger; Gunnar Soderdahl; Simone I Strasser; Karl-Walter Jauch; Peter Neuhaus; Hans J Schlitt; Edward K Geissler Journal: BMC Cancer Date: 2010-05-11 Impact factor: 4.430
Authors: Alexander E Perl; Margaret T Kasner; Donald E Tsai; Dan T Vogl; Alison W Loren; Stephen J Schuster; David L Porter; Edward A Stadtmauer; Steven C Goldstein; Noelle V Frey; Sunita D Nasta; Elizabeth O Hexner; Jamil K Dierov; Cezary R Swider; Adam Bagg; Alan M Gewirtz; Martin Carroll; Selina M Luger Journal: Clin Cancer Res Date: 2009-10-20 Impact factor: 12.531
Authors: Joseph D Coppock; Bryant G Wieking; Alfredo A Molinolo; J Silvio Gutkind; W Keith Miskimins; John H Lee Journal: Neoplasia Date: 2013-06 Impact factor: 5.715
Authors: Helga Weber; Pamela Leal; Stefan Stein; Hana Kunkel; Patricia García; Carolina Bizama; Jaime A Espinoza; Ismael Riquelme; Bruno Nervi; Juan C Araya; Manuel Grez; Juan C Roa Journal: Oncotarget Date: 2015-10-13